C. Klinkenstein

Acute Toxicity of Mitoxantrone, Chlorambucil and Prednisolone (MCP) versus MCP plus Rituximab in Low-Grade Non-Hodgkin’s Lymphoma – Interim Results of a Phase III Trial

D. Huhn, M. Herold, J. Ströhl, 2000, Oncology Research and Treatment.

Band 23, Heft 2, April 2000

C. Rübe, D. Huhn, C. Santjohanser, 2000, Oncology Research and Treatment.

Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy--a pilot study of the German Myeloma Treatment Group (GMTG).

H. Deicher, K. Schumacher, C. Klinkenstein, 1996, European journal of cancer.

Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia

D. Huhn, B. Dörken, W. Ludwig, 1998 .

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

D. Niederwieser, T. Ittel, R. Naumann, 2004 .

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

D. Niederwieser, M. Herold, A. Franke, 2006, Journal of Cancer Research and Clinical Oncology.

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

T. Ittel, R. Naumann, K. Höffken, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Results in Adult AML: Comparison of Postremission Chemotherapy vs. Autologous BMT vs. Allogeneic BMT

M. Stauch, R. Schubert, R. Rohrberg, 1996 .